Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QRX-3 in Ambulatory Chronic Kidney Patients
NCT06948292Phase 2Completed
- Sponsor
- Ebima Clifford Okundaye
- Start
- Mar 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of QRX-3 in chronic kidney disease (CKD), diabetic kidney disease (DKD) and hypertensive kidney disease (HKD) (2 arms), sponsored by Ebima Clifford Okundaye. Primary endpoint: Daily change in glomerular filtration rate at 12 months. Started Mar 2023; status: completed.
02
Drugs
QRX-3
03
Conditions
chronic kidney disease (CKD)diabetic kidney disease (DKD)hypertensive kidney disease (HKD)
Beyond the preview
Go deeper on NCT06948292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06948292.